More Competitors and Compatibility Opens Up Multi-Billion-Dollar Gene Expression Analysis Market

NEW YORK, Jan. 15 /PRNewswire/ -- New products and applications have made gene expression analysis a significantly more competitive market in the past few years, which will lead to a market worth nearly $2.5 billion by 2012, according to a new study released today from Kalorama Information. Real-time PCR, improvements in microarrays, and the increasing reality of clinical application beyond the research bench will propel double-digit growth in this segment for the next 5 years, according to the study.

The new study, Gene Expression Profiling Markets, found that gene expression analysis has progressed significantly in the past two years with the emergence of a number of new techniques and technologies impacting the market, including next-generation sequencers, SNP analysis, copy number variation, methylation analysis, alternative splicing analysis, ChIP-on-chip, and micro RNA technology. In addition, better standardization and compatibility among technologies and increasing clarity regarding regulatory issues are fueling healthy competition.

"The perception that the Affymetrix platform is the only reliable, reproducible platform available is changing," notes Justin Saeks, analyst for Kalorama Information and the author of the study. "Customers thought they would never be able to compare legacy data with new data from other platforms; however, it has now been demonstrated that these fears are not justified, which has opened up the market to a host of new product introductions."

Kalorama Information's report Gene Expression Profiling Markets, provides market forecasts through 2012 for microarrays, instruments and reagents, as well as real-time PCR. It establishes competitive market share in gene expression analysis, segments revenues regionally, identifies market challenges, and discusses strategic recommendations for manufacturers. The study also reviews new technologies available and in development, recent business deals and alliances, progress on standardization and regulatory guidance, and developments in new clinical applications just now emerging. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Gene-Expression-Profiling-1430119.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or [email protected], or visit http://www.KaloramaInformation.com.

SOURCE Kalorama Information

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.